1. Catalog
  2. Nodes
  3. a(CHEBI:"desferrioxamine B")

a(CHEBI:"desferrioxamine B")

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
desferrioxamine B
Namespace
chebi
Namespace Version
20180906
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns

Appears in Networks 1

Heme Curation v0.0.1-dev

Mechanistic knowledge surrounding heme

In-Edges 15

a(MESH:"Complement Membrane Attack Complex") negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

DFX also reduced the MAC content in the clot at day-3 (33.0 ± 6.6 vs. 56.2 ± 9.2 ng/g in the vehicle-treated group, p<0.05, Fig. 5B). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

a(MESH:"Complement Membrane Attack Complex") negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

The present study found that DFX treatment reduces MAC formation in the clot. PubMed:27125525

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Stroke
Text Location
Discussion

bp(GO:"necroptotic process") negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

Heme-induced necroptosis is reversed by deferoxamine, a Fe chelator. PubMed:24904418

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Liver
MeSH
Malaria
Text Location
Review

bp(HM:"macrophage M1 polarization") negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

Treatment with Hx or DFO diminished the increase of some M1 polarization markers in BMDMs following treatment with hemolytic RBCs (supplemental Figure 14). PubMed:26675351

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Liver
MeSH
Anemia, Sickle Cell
Text Location
Results

p(HGNC:HBB) positiveCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

We found that hemoglobin contents in hematoma were significantly higher in the DFX treated group compare to the vehicle-treated group (15.9 ± 1.8 vs. 11.8 ± 0.8 mg/g, p<0.05, Fig. 5A). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

complex(a(CHEBI:"desferrioxamine B"), a(CHEBI:heme)) hasComponent a(CHEBI:"desferrioxamine B") View Subject | View Object

Appears in Networks:

p(HGNC:CD163) negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

DFX treatment also caused a significant reduction in infiltrating CD163-positive and HO-1 positive cell in the hematoma at day 3 (Figs. 6A and B) and day 7 (Suppl Figures II & III). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

p(HGNC:CD47) positiveCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

The loss of CD47 in the clot was reduced significantly by DFX treatment at day 3 (CD47/GAPDH: 1.32 ± 0.16 in ICH+DFX group vs. 0.74 ± 0.07 in ICH + vehicle group, p<0.05, Fig. 5C) and day 7 (p<0.01, Suppl Figure I). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

p(HGNC:CD47) positiveCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

DFX also reduced CD47 loss and microglia/macrophage infiltration after ICH suggesting it also affects erythrophagocytosis. PubMed:27125525

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Stroke
Text Location
Discussion

p(HGNC:HMOX1) negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

DFX treatment also caused a significant reduction in infiltrating CD163-positive and HO-1 positive cell in the hematoma at day 3 (Figs. 6A and B) and day 7 (Suppl Figures II & III). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

p(HGNC:HMOX1) negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

Western blot analysis showed that the protein expression of HO-1 was decreased in the hematoma in the DFX treated group at day 3( HO-1/GAPDH: 0.32 ± 0.04 vs. 0.98 ± 0.07 in the vehicle-treated group, p<0.05, Fig. 6B) and day 7 (p<0.05, Suppl Figure III). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

path(MESH:"Brain Edema") negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

There was a tendency that lysed RBC-induced brain edema was less in deferoxamine-treated group (brain water content in the ipsilateral hemisphere: 79.8±0.6% vs. 80.5±0.7% in the saline coinjection group, n¼6, P40.05). PubMed:24667910

Appears in Networks:
Annotations
MeSH
Ependyma
Text Location
Results

path(MESH:Hematoma) negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

In combination, these finding may underlie our previous results showing that DFX slows hematoma resolution after ICH in aged rats 12. PubMed:27125525

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Cerebral Hemorrhage
Text Location
Discussion

path(MESH:Hydrocephalus) negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

Coinjection of deferoxamine with lysed RBC reduced ventricular enlargement (47.8±17.8 vs. 59.9±15.7mm3 in saline coinjection group, Po0.05, Figure 6). PubMed:24667910

Appears in Networks:
Annotations
MeSH
Ependyma
Text Location
Results

path(MESH:Hydrocephalus) negativeCorrelation a(CHEBI:"desferrioxamine B") View Subject | View Object

The major findings of this study are (1) intraventricular injection of lysed RBCs but not packed RBCs resulted in hydrocephalus; (2) lysed RBCs upregulated brain HO-1 and ferritin levels; (3) intraventricular injection of iron also caused hydrocephalus; and (4) iron chelation with deferoxamine reduced lysed RBC-induced hydrocephalus. PubMed:24667910

Appears in Networks:
Annotations
MeSH
Ependyma
Text Location
Discussion

Out-Edges 18

a(CHEBI:"desferrioxamine B") positiveCorrelation p(HGNC:CD47) View Subject | View Object

DFX also reduced CD47 loss and microglia/macrophage infiltration after ICH suggesting it also affects erythrophagocytosis. PubMed:27125525

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Stroke
Text Location
Discussion

a(CHEBI:"desferrioxamine B") negativeCorrelation p(HGNC:CD163) View Subject | View Object

DFX treatment also caused a significant reduction in infiltrating CD163-positive and HO-1 positive cell in the hematoma at day 3 (Figs. 6A and B) and day 7 (Suppl Figures II & III). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

a(CHEBI:"desferrioxamine B") negativeCorrelation p(HGNC:HMOX1) View Subject | View Object

DFX treatment also caused a significant reduction in infiltrating CD163-positive and HO-1 positive cell in the hematoma at day 3 (Figs. 6A and B) and day 7 (Suppl Figures II & III). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

a(CHEBI:"desferrioxamine B") negativeCorrelation path(MESH:Hydrocephalus) View Subject | View Object

Coinjection of deferoxamine with lysed RBC reduced ventricular enlargement (47.8±17.8 vs. 59.9±15.7mm3 in saline coinjection group, Po0.05, Figure 6). PubMed:24667910

Appears in Networks:
Annotations
MeSH
Ependyma
Text Location
Results

a(CHEBI:"desferrioxamine B") negativeCorrelation path(MESH:Hydrocephalus) View Subject | View Object

The major findings of this study are (1) intraventricular injection of lysed RBCs but not packed RBCs resulted in hydrocephalus; (2) lysed RBCs upregulated brain HO-1 and ferritin levels; (3) intraventricular injection of iron also caused hydrocephalus; and (4) iron chelation with deferoxamine reduced lysed RBC-induced hydrocephalus. PubMed:24667910

Appears in Networks:
Annotations
MeSH
Ependyma
Text Location
Discussion

a(CHEBI:"desferrioxamine B") negativeCorrelation path(MESH:"Brain Edema") View Subject | View Object

There was a tendency that lysed RBC-induced brain edema was less in deferoxamine-treated group (brain water content in the ipsilateral hemisphere: 79.8±0.6% vs. 80.5±0.7% in the saline coinjection group, n¼6, P40.05). PubMed:24667910

Appears in Networks:
Annotations
MeSH
Ependyma
Text Location
Results

a(CHEBI:"desferrioxamine B") negativeCorrelation bp(GO:"necroptotic process") View Subject | View Object

Heme-induced necroptosis is reversed by deferoxamine, a Fe chelator. PubMed:24904418

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Liver
MeSH
Malaria
Text Location
Review

a(CHEBI:"desferrioxamine B") negativeCorrelation bp(HM:"macrophage M1 polarization") View Subject | View Object

Treatment with Hx or DFO diminished the increase of some M1 polarization markers in BMDMs following treatment with hemolytic RBCs (supplemental Figure 14). PubMed:26675351

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Liver
MeSH
Anemia, Sickle Cell
Text Location
Results

a(CHEBI:"desferrioxamine B") positiveCorrelation p(HGNC:HBB) View Subject | View Object

We found that hemoglobin contents in hematoma were significantly higher in the DFX treated group compare to the vehicle-treated group (15.9 ± 1.8 vs. 11.8 ± 0.8 mg/g, p<0.05, Fig. 5A). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

a(CHEBI:"desferrioxamine B") negativeCorrelation a(MESH:"Complement Membrane Attack Complex") View Subject | View Object

DFX also reduced the MAC content in the clot at day-3 (33.0 ± 6.6 vs. 56.2 ± 9.2 ng/g in the vehicle-treated group, p<0.05, Fig. 5B). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

a(CHEBI:"desferrioxamine B") negativeCorrelation a(MESH:"Complement Membrane Attack Complex") View Subject | View Object

The present study found that DFX treatment reduces MAC formation in the clot. PubMed:27125525

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Stroke
Text Location
Discussion

a(CHEBI:"desferrioxamine B") decreases path(MESH:Hemolysis) View Subject | View Object

These results suggested that the treatment of DFX reduced the process of hemolysis after ICH, which might be due to alleviating MAC formation. PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

a(CHEBI:"desferrioxamine B") positiveCorrelation p(HGNC:CD47) View Subject | View Object

The loss of CD47 in the clot was reduced significantly by DFX treatment at day 3 (CD47/GAPDH: 1.32 ± 0.16 in ICH+DFX group vs. 0.74 ± 0.07 in ICH + vehicle group, p<0.05, Fig. 5C) and day 7 (p<0.01, Suppl Figure I). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

a(CHEBI:"desferrioxamine B") negativeCorrelation p(HGNC:HMOX1) View Subject | View Object

Western blot analysis showed that the protein expression of HO-1 was decreased in the hematoma in the DFX treated group at day 3( HO-1/GAPDH: 0.32 ± 0.04 vs. 0.98 ± 0.07 in the vehicle-treated group, p<0.05, Fig. 6B) and day 7 (p<0.05, Suppl Figure III). PubMed:27125525

Appears in Networks:
Annotations
MeSH
Cerebral Hemorrhage
Text Location
Results

a(CHEBI:"desferrioxamine B") negativeCorrelation path(MESH:Hematoma) View Subject | View Object

In combination, these finding may underlie our previous results showing that DFX slows hematoma resolution after ICH in aged rats 12. PubMed:27125525

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Cerebral Hemorrhage
Text Location
Discussion

a(CHEBI:"desferrioxamine B") decreases bp(MESH:"Bacterial Load") View Subject | View Object

Chelation of growth-medium iron with deferoxamine (DFO, 10 μM) led to a reduction in bacterial growth, as compared with non-chelated controls (Fig. 2a). PubMed:27798618

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
MeSH
Plasma
MeSH
Sepsis
Text Location
Results

a(CHEBI:"desferrioxamine B") decreases p(MGI:Slc40a1) View Subject | View Object

Expectedly, and in line with previous report (13), treatment of macrophages with DFO abolished ferroportin and ferritin induction by heme, whereas TfR1 expression was lowered upon heme and combined treatment with heme and DFO (Fig. 7D). PubMed:29212341

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
Text Location
Results

a(CHEBI:"desferrioxamine B") decreases p(MGI:Ftl1) View Subject | View Object

Expectedly, and in line with previous report (13), treatment of macrophages with DFO abolished ferroportin and ferritin induction by heme, whereas TfR1 expression was lowered upon heme and combined treatment with heme and DFO (Fig. 7D). PubMed:29212341

Appears in Networks:
Annotations
Cell Ontology (CL)
macrophage
Text Location
Results

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.